AlzeCure Pharma AB announced that its abstract on NeuroRestore ACD856 has been accepted for presentation at the AD/PD 2025 ...

The European Commission (EC) has approved the marketing authorisation for LAZCLUZE (lazertinib) in combination with RYBREVANT ...

The UK experienced a notable increase in advanced therapy clinical trials in 2024, reaching 187 ongoing trials. This marks a ...

Datapharm has announced its expansion into the United States through a new partnership with phactMI. The collaboration aims ...

Biofidelity and CellCarta have announced a strategic partnership to utilise Biofidelity’s Aspyre® Lung in global clinical ...

Cambridge Cognition Holdings plc has expanded its partnership with Actinogen Medical Limited for the phase 2b/3 XanaMIA Alzheimer’s disease trial.

Owlstone Medical has announced a first close of $27 million (circa £22 million) in its Series E financing round. The round ...

Oxford Drug Design, the Oxford-based AI drug discovery company, has announced further in vivo validation for its ...